Steadcare Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-12-2024
- Paid Up Capital ₹ 0.10 M
as on 07-12-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue -1.67%
(FY 2021)
- Profit -51.24%
(FY 2021)
- Ebitda -69.66%
(FY 2021)
- Net Worth 25.36%
(FY 2021)
- Total Assets 4.16%
(FY 2021)
About Steadcare Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rosy Goyal and Lavish Goyal serve as directors at the Company.
- CIN/LLPIN
U24232PB2014PTC038776
- Company No.
038776
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2014
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Rupnagar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Steadcare Lifesciences Private Limited offer?
Steadcare Lifesciences Private Limited offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Digestive System Drugs & Medicines, Antacid Drugs, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Pharmaceutical Medicine, Pain Relief Drugs & Pharmaceuticals.
Who are the key members and board of directors at Steadcare Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rosy Goyal  | Additional Director | 18-Feb-2015 | Current |
| Lavish Goyal | Director | 28-Jul-2014 | Current |
Financial Performance of Steadcare Lifesciences.
Steadcare Lifesciences Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 1.67% decrease. The company also saw a substantial fall in profitability, with a 51.24% decrease in profit. The company's net worth Soared by an impressive increase of 25.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Steadcare Lifesciences?
In 2021, Steadcare Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Steadcare Lifesciences?
Unlock and access historical data on people associated with Steadcare Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Steadcare Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Steadcare Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
